NCT01254890 - Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Leukemia

Interventions

DRUG

Azacitidine

75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.

DRUG

Sorafenib

Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston